Actively Recruiting
Interest of Myo-inositol Supplementation in Women With Polycystic Ovarian Syndrome
Led by University Hospital, Lille · Updated on 2026-04-22
276
Participants Needed
1
Research Sites
220 weeks
Total Duration
On this page
Sponsors
U
University Hospital, Lille
Lead Sponsor
M
Ministry of Health, France
Collaborating Sponsor
AI-Summary
What this Trial Is About
The main objective will be to check if MyoInositol (MYO) reduces the total resistance rate to Clomiphene Citrate (CC). For this, our study will be controlled, randomized and double blinded. It will include patients with PCOS (polycystic ovary syndrome, defined by the Rotterdam criteria) who wish to become pregnant and are eligible to simple ovulation induction by CC. Half of them will receive MYO + levomefolic acid (5-MTHF) in addition to the CC, while the other half will receive a placebo containing only 5-MTHF in addition to the CC. The MYO supplementation will be initiated at least one month before taking CC and will be continued throughout this treatment until pregnancy or before switching to another type of treatment for ovulation induction if no pregnancy is obtained after 6 ovulatory cycles.
CONDITIONS
Official Title
Interest of Myo-inositol Supplementation in Women With Polycystic Ovarian Syndrome
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Wishing pregnancy
- Diagnosed with PCOS by Rotterdam criteria: high antral follicle count (> 19 per ovary), cycle disorder, or hyperandrogenism (at least two of these)
- Never treated with Clomiphene Citrate (CC) or stopped CC treatment more than 3 months ago
- Provided informed consent
- Covered by social security
You will not qualify if you...
- Intolerance to Clomiphene Citrate (CC) in previous treatment
- Body mass index (BMI) over 35
- Other causes of oligoanovulation needing specific treatment (e.g., Hyperprolactinemia or functional hypothalamic anovulation)
- Currently pregnant at start of CC treatment
- Other male or female causes of fertility problems
- History of ovarian drilling
- Negative rubella antibody test
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
CHU de Lille hôpital Jeanne de Flandre
Lille, France
Actively Recruiting
Research Team
G
Goeffrey ROBIN, MD
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
TRIPLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here